دورية أكاديمية
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
| العنوان: | Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. |
|---|---|
| المؤلفون: | Conteduca, Vincenza, Jayaram, Anuradha, Romero-Laorden, Nuria, Wetterskog, Daniel, Salvi, Samanta, Gurioli, Giorgia, Scarpi, Emanuela, Castro, Elena, Marin-Aguilera, Mercedes, Lolli, Cristian, Schepisi, Giuseppe, Maugeri, Antonio, Wingate, Anna, Farolfi, Alberto, Casadio, Valentina, Medina, Ana, Puente, Javier, Vidal, Mª José Méndez, Morales-Barrera, Rafael, Villa-Guzmán, Jose C, Hernando, Susana, Rodriguez-Vida, Alejo, González-Del-Alba, Aránzazu, Mellado, Begoña, Gonzalez-Billalabeitia, Enrique, Olmos, David, Attard, Gerhardt, De Giorgi, Ugo |
| سنة النشر: | 2018 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Androgen receptor, Androgen receptor–directed therapies, Biomarker, Castration-resistant prostate cancer, Docetaxel, Plasma DNA, Androgen Antagonists, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Humans, Kallikreins, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Progression-Free Survival, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Spain, Time Factors |
| الوصف: | Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1873-7560 |
| العلاقة: | http://hdl.handle.net/10668/13576Test; PMC6377278; https://doi.org/10.1016/j.eururo.2018.09.049Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/pdfTest |
| DOI: | 10.1016/j.eururo.2018.09.049 |
| الإتاحة: | https://doi.org/10.1016/j.eururo.2018.09.049Test http://hdl.handle.net/10668/13576Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377278/pdfTest |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.7E3380C5 |
| قاعدة البيانات: | BASE |
| تدمد: | 18737560 |
|---|---|
| DOI: | 10.1016/j.eururo.2018.09.049 |